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ABSTRACT

Wright, Breanne N. M.S., Purdue University, August 2014. Iron Nutrition following
Roux-en-Y Gastric Bypass Surgery. Major Professor: Nana Gletsu-Miller.
Roux-en-Y gastric bypass surgery (RYGB) is effective for weight loss, but
is commonly associated with iron deficiency and its clinical manifestation, anemia.
Diagnosing iron deficiency is complex because iron status depends on other
nutrients; additionally, anemia following surgery is not specifically due to
deficiency in iron, as it can be due to deficiencies in other nutrients including zinc,
copper, vitamin B6, folate, and vitamin B12. In patients who have undergone
RYGB, our aims were to 1) conduct a comprehensive assessment of nutrients
involved in iron homeostasis, 2) determine the contribution of dietary intake to
iron deficiency, and 3) describe associations between anemia and nutritional
status of iron and other nutrients. Systemic measures of hemoglobin, ferritin,
serum transferrin receptor (sTfR), total iron binding capacity (TIBC), copper (Cu),
vitamins B6 and B12, folate, zinc (Zn), and C-reactive protein (CRP) were
determined using reference methods. Iron deficiency equaled having ≥ 2
abnormalities in: ferritin, sTfR, sTfR:ferritin, or TIBC. Ferritin, a measure of iron
stores, was defined as normal (ferritin ≥ 20 mcg/L) or low (ferritin < 20 mcg/L).
Statistics included prevalence, mean ± standard error of the mean (s.e.m.) for
normally-distributed data, median ± semi-interquartile range for skewed data

viii
(indicated with an asterisk [*]), frequency tables, t-tests (independent, by group),
correlations, and general linear models (significant if p < 0.05). Subjects (N=70)
were 91% female, age 49 ± 1 years, *4 ± 2 years post surgery, and 79%
Caucasian. Fifty-six percent of the total population and 96% of the subpopulation
with anemia (N=26) presented with deficiencies related to iron nutriture, including
deficiencies in iron, zinc, copper, vitamin B6, folate, and vitamin B12. The most
prevalent nutrient deficiencies in the total population and the subpopulation with
anemia were iron and zinc; prevalence of iron and zinc deficiency in the total
population was 24.3% and 20.0%, respectively, and prevalence of iron and zinc
deficiency in the subpopulation with anemia was 46.2% and 23.1%, respectively.
Participants in the total population and the subpopulation with anemia were also
deficient in copper, vitamin B6, vitamin B12, and folate (11.5% and 26.9%,
respectively).

In the total population, iron and zinc deficiency occurred in

isolation and also in combination with other nutrient deficiencies; all other nutrient
deficiencies occurred in combination. In the subpopulation with anemia, only iron
deficiency occurred in isolation. The dietary intake of the study population
exceeded the RDAs for all nutrients assessed. In addition, patients with low
ferritin concentrations consumed lower total energy (p= 0.009), fat (p= 0.026),
protein (p=0.013), and animal protein (p=0.023), compared to patients with
normal ferritin concentrations. Dietary intake of heme iron was correlated with
years post-RYGB surgery (r=0.67, p<0.05). In conclusion, in a community-based
surveillance of RYGB patients we found that, more often than not, RYGB patients
presented with micronutrient deficiencies related to iron nutriture; this includes
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deficiencies in iron, copper, zinc, vitamin B6, folate, and vitamin B12. It was more
likely for multiple deficiencies to occur simultaneously than for deficiencies to
occur alone. In addition, there was a high prevalence of anemia, a clinical
manifestation of deficiencies in these nutrients. Implications of these findings are
that clinicians who evaluate post-RYGB patients, especially patients who present
with known symptoms or manifestations of iron deficiency, should also screen
patients for deficiencies in copper, zinc, vitamin B 6, folate, and vitamin B12, as
these

deficiencies

are

also

prevalent

following

surgery,

may

occur

simultaneously with iron deficiency, and are also implicated in anemia. Based on
our findings that RYGB patients who have more favorable iron stores consume
more energy, fat, and protein than patients with low iron stores, increasing
protein intake following surgery may improve iron status; although, increasing
consumption of fat may have detrimental effects on weight regain in the RYGB
population. Findings of this study may be used to enhance prophylactic
measures and treatments for iron deficiency following RYGB.

1

CHAPTER 1. INTRODUCTION

1.1

Obesity and its Health Consequences

Obesity is a significant health problem resulting in many comorbidities
including diabetes, cardiovascular disease and cancer.1 Rates of moderate and
severe obesity are continuing to rise in the United States. 2 Although obesity is
generally thought of as a condition of overnutrition, overweight and obesity are
also known risk factors for deficiencies in various micronutrients, including
vitamins A, E, B1 and B12, folate, selenium, chromium, zinc, and iron.3,4 In
particular, a high prevalence of iron deficiency is documented in the severely
obese population (28%-35%).5-7 Bariatric weight loss surgery is growing in
popularity as an effective, long-term treatment for moderate and severe obesity,
but is also associated with iron deficiency (postoperative prevalence: 15-54%8-12).
This chapter discusses iron deficiency, factors that contribute to iron homeostasis,
the clinical manifestation of anemia, mechanisms for iron deficiency in obesity,
and mechanisms for iron deficiency following bariatric surgery.
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1.2

Iron Deficiency and Homeostasis
1.2.1 Iron Deficiency

Iron deficiency is the most common and widespread nutritional disorder in
the world, and the only nutrient deficiency that is significantly prevalent in
industrialized nations.13,14 It is associated with increased infant mortality and
perinatal risks for mothers and neonates, it adversely affects cognitive
performance, behavior, and physical growth of infants and adolescents, as well
as immune status, morbidity from infections, physical capacity, and work
performance in all age groups.13 Therefore, patients who develop iron deficiency
have a decreased quality of life. Severe iron deficiency is associated with low
blood concentrations of hemoglobin, and is termed iron deficiency anemia
(IDA).13

1.2.1.1 Causes
The causes of iron deficiency are multifactorial. Iron deficiency may be
caused by blood loss due to disease, infection, hemorrhage in childbirth,
menstruation, or trauma. Iron deficiency may also be nutrient-related as a
consequence of poor diet quality, such as low intake of bioavailable iron, deficits
in specific nutrients, e.g. copper, vitamin B6 and zinc which are required for iron
absorption and heme synthesis, or high concentrations of nutrients that compete
with iron for absorption. The cause of iron deficiency may also be systemic,
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referring to the physiological state of the host, such as inflammation and/or
mechanical alterations due to gastrointestinal surgery.4
The multifactorial etiology of iron deficiency includes true and functional
iron deficiency. The former is characterized by reduced iron stores, while the
latter describes a compromised supply of iron to tissues and/or mobilization of
iron between tissues. Functional iron deficiency can be affected by conditions
such as obesity-induced inflammation and thus is highly dependent on the
systemic state of the individual.

1.2.2 Iron Homeostasis
Because of iron’s central role in oxygen and energy metabolism, iron
absorption, utilization and storage are tightly regulated to maintain homeostasis.
Unlike other essential elements, iron is highly conserved. Total iron body content
is estimated to be 3800 mg in men and 2300 mg in women; relatively small
amounts of iron are lost in feces (~0.6 mg/day), urine (<0.1 mg/day) and sweat
(<0.3 mg/day).15 Because there are no other excretion routes for iron and iron is
mainly lost through blood, fecal iron content can be used to indirectly measure
iron absorption. Approximately 20 to 25 mg of iron is recycled daily with the
erythrophagocytosis of senescent red blood cells in the spleen, and iron that is
released from heme is captured and reutilized to produce new erythrocytes in
bone marrow.15 The body also contains a large storage pool for iron (in its
storage form- ferritin), mainly in the liver, spleen and bone marrow.
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1.2.2.1 Intestinal Iron Absorption
1.2.2.1.1 Heme and Non-Heme Iron
There are two bioavailable forms of iron that are obtained from the diet:
heme and non-heme iron. The more bioavailable heme iron is found in meat, fish
and poultry; about 40% of the iron is bound into heme while the other 60% is
non-heme iron.16 The form of iron primarily found in grains, vegetables and
legumes is non-heme iron. For meat-eating individuals, heme iron makes up
about two-thirds of the iron that is absorbed. Heme iron is soluble at the pH of the
duodenum where most iron absorption occurs, and is not affected by the dietary
constituents that impair non-heme iron absorption such as phytates, polyphenols,
oxalates, calcium and other divalent cation minerals.17 Co-consumption with
vitamin C - rich foods,18-21 and meat, fish and poultry22-25 enhances non-heme
iron absorption.17,26 There is a high incidence of iron deficiency anemia in
countries where meat is less available because of the predominance of nonheme iron-containing foods in the diet.27

1.2.2.1.2 Mechanism for Intestinal Iron Absorption
Iron homeostasis is controlled at the level of intestinal absorption. Iron
absorption is an important determinant of iron homeostasis and is highly
regulated. Iron absorption increases when iron stores are low and decreases
when iron stores are high. Uptake of non-heme iron by enterocytes is better
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understood than heme iron. The abbreviated mechanism of iron passage across
the enterocyte is shown in figure 1.1:28

Figure 1.1 Iron Passage Across the Enterocyte. Ferric iron is reduced by the
brush border ferric reductase, Dcytb, before being transported into the cell via
Dmt1. Iron is either stored as ferritin or exported into the circulation across the
basolateral membrane via Fpn1. The iron oxidase, Hp, converts ferrous iron to
ferric iron for efficient export. Iron circulates bound to Tf. Liver-derived Hepcidin
reflects systemic iron demands, and removes Fpn1 from the plasma membrane
in order to prevent iron export.
First, the membrane-bound ferroxidase duodenal cytochrome b (Dcytb)
reduces ferric iron (Fe3+) to ferrous iron (Fe2+). Then, divalent metal transporter-1
(Dmt1) transfers molecular Fe2+ from the luminal side into the enterocyte. Iron
entering the enterocyte is either incorporated into ferritin, the storage form of iron,
or subjected to basolateral export by transmembrane protein ferroportin 1 (Fpn1).
Ferrous iron then undergoes oxidation by the membrane-bound coppercontaining ferroxidase hephaestin (Hp) before being incorporated into transferrin,
the mobile form of iron, and entering circulation. 29 It is important to note that, in
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addition to intestinal absorptive cells, ferroportin is on the surface of hepatocytes,
macrophages and placental cells, all of which release iron into the plasma. 30
Hepcidin is a liver-derived peptide implicated in the control of iron homeostasis.
Hepcidin inhibits iron absorption by binding to ferroportin, targeting its
degradation, and ultimately blocking iron efflux.28,29 Therefore, hepcidin blocks
intestinal iron absorption and release in various cell types. Genes associated with
hereditary hemochromatosis (a genetic disease causing the body to absorb too
much iron), HFE and TFR2, have been found to regulate hepcidin levels through
an iron-sensing mechanism.15,31-33

1.2.2.2 Heme Synthesis
Most body iron is found as heme iron; heme is the essential constituent for
oxygen transport and storage, electron transport in aerobic respiration and signal
transduction. Therefore, the synthesis of heme iron is vital. Heme synthesis
occurs primarily in bone marrow, where red blood cells are synthesized, and in
the liver to carry out its function in the cytochrome system. Of importance is that
heme synthesis relies on vitamin B6 and zinc, thus deficiencies in these nutrients
negatively impact iron homeostasis.

1.2.2.3 Iron Toxicity
Chronic iron toxicity can be associated with high dietary iron intake,
frequent blood transfusions, and hemochromatosis, a genetic disease associated
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with increased iron absorption.34 However, there are mechanisms in place to
prevent toxic accumulation of iron, including the upregulation of hepcidin to
reduce iron absorption, induction of ferritin to limit the availability of iron and the
induction of antioxidant enzymes for protection against oxidant damage. 35
Therefore, the risk of iron toxicity is low.

1.2.3 Assessment of Iron Status
There are several methods of assessing iron status and diagnosing iron
deficiency, and the precise cutoff values often differ by laboratory. The most
specific test for depletion of iron storage is low serum ferritin. However, ferritin is
an acute-phase protein and is thus increased in a state of chronic or acute
inflammation.36,37 Therefore, this method is not always reliable since high ferritin
may occur during conditions of low iron status. Serum iron, the amount of iron in
the blood, is not representative of the amount of iron stored in the body, and
therefore this test is rarely informative on its own.38 Transferrin is a protein that
transports iron in blood via reversible binding. Total iron-binding capacity (TIBC)
measures how much of transferrin in circulation is iron-free.38 Thus, elevated
TIBC indicates poor iron status. Transferrin saturation index is the ratio of serum
iron to TIBC and represents how much serum iron is bound to transferrin. Low
transferrin saturation indicates iron deficiency. The soluble form of transferrin
receptor present in serum (sTfR) is proportional to the amount of surface
receptors;15 sTfR expression is translationally regulated and is increased when
iron stores are low.
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1.3

Anemia

The widely known clinical manifestation of iron deficiency is anemia.
Anemia is generally characterized by low hemoglobin concentrations (<12 g/dL
for menstruating females and <13 g/dL for men and post-menopausal females).
The World Health Organization (WHO) estimates that 39% of children less than 5
years of age, 48% of 5-14 year-old children, and 42% of women in developing
countries suffer from anemia, but iron deficiency is present in only half of these
individuals.13 Anemia is also a consequence of deficiencies in other nutrients
including copper, vitamins B6 and B12, folate, and zinc, which adds to the
complexity of effectively diagnosing and treating iron deficiency. Anemia resulting
from iron, copper and vitamin B6 deficiency is characterized as microcytic, while
anemia due to deficiency in vitamin B12 and folate are characterized as
megaloblastic.

1.3.1 Microcytic Anemia: Iron, Copper and Vitamin B6 Deficiency
1.3.1.1 Iron Deficiency Anemia (IDA)
Severe iron deficiency is accompanied by microcytic, hypochromic anemia
and is termed IDA.36,37 IDA is characterized by the aforementioned measures of
iron depletion, as well as low mean corpuscular hemoglobin (MCH) and mean
corpuscular volume (MCV), and high red blood cell width (RDW).15
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1.3.1.1.1 IDA Secondary to Copper Deficiency
IDA may also occur secondary to copper deficiency. Hephaestin is a
copper-containing ferroxidase that oxidizes ferrous iron to ferric iron, enabling
iron to bind transferrin and enter circulation.39 Therefore, copper deficiency may
also lead to functional iron deficiency and IDA.39

1.3.1.2 Vitamin B6 and Zinc Deficiency
Vitamin B6 and zinc are required for heme synthesis, and therefore
deficiencies in these nutrients may result in anemia. Similar to iron deficiency
anemia, vitamin B6 (pyridoxine) deficiency can manifest as microcytic,
hypochromic anemia (low MCH and low MCV), but with normal or high serum
concentrations of iron and ferritin.40 This type of anemia is generally named
sideroblastic anemia,41 referring to ringed sideroblasts in the bone marrow,42 and
is thought to be caused by insufficient hematopoiesis due to faulty heme
synthesis.43 Pyridoxine-responsive anemia44 belongs to this group, as pyridoxine
acts as a coenzyme in the process of heme synthesis.40 Since zinc is also
required for heme synthesis, zinc deficiency may also manifest as microcytic,
hypochromic anemia; however, there is a lack of evidence to support this in the
literature. Therefore, in addition to iron and copper, deficiency in vitamin B6 and
zinc may result in microcytic anemia.
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1.3.2 Megaloblastic Anemia: Vitamin B12 and Folate Deficiency
Vitamin B12 and folate are important for the normal maturation of all cells,
as they are needed for cell differentiation.45 Vitamin B12 and folic acid deficiency
are characterized by megaloblastic anemia, which affects the development and
morphology of blood cells. The anemia of folic acid deficiency has morphologic
features indistinguishable from those of vitamin B12 deficiency, but it develops
much more rapidly.

15,46-48

The cellular hallmarks are macrocytosis, which is

easily detected by elevated erythroid MCV but not specific to megaloblastic
anemia, and abnormal nuclear maturation that is more specific than
macrocytosis.15,45 However, normocytic anemia (normal MCV) may be attributed
to vitamin B12 and folate deficiency anemia in persons with coexisting
microcytosis, possibly caused by iron deficiency anemia, which can blunt or
eliminate the expected macrocytosis.49,50 Therefore, vitamin B12 and folate can
lead to anemia; however, this type of anemia is characterized by macrocytosis,
and thus may be distinguishable from microcytic anemia caused by iron, copper,
vitamin B6 and zinc deficiency.

1.3.3 Anemia of Chronic Disease (ACD)
Anemia of Chronic Disease (or Anemia of Inflammation) may accompany
chronic illness or inflammation, and is a protective mechanism that the body uses
to limit the amount of iron that is available to harmful pathogens.51 When this
defense system is activated, less iron is absorbed and excess iron is collected by
macrophages and stored in the liver, resulting in a rise in ferritin and a decrease
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in hemoglobin concentrations.51 There are three known mechanisms for ACD,
which are all related to abnormal cytokine levels: 1) Dmt1 is upregulated and
Fpn1 is downregulated by lipopolysaccharides, interferon-γ, and tumor necrosis
factor-α (TNF-α), causing an increase in iron uptake by reticuloendothelial cells;
2) Hepcidin is upregulated by lipopolysaccharides, interleukin 6 (IL-6), and
possible interleukin-1 (IL-1), causing a reduction in iron absorption; 3) Erythroid
progenitor expansion is inhibited by interferon-γ, IL-1, TNF-α, and interferon-β,
causing disruption of red blood cell production.52

Patients with chronic or

inflammatory disease are identified with high serum C reactive protein (CRP), low
hemoglobin concentrations and low transferrin saturation.15,51 Because patients
who have IDA may also have co-existing inflammation, it is difficult to
differentiate between ACD and IDA. Since serum ferritin concentrations may be
increased in patients who are inflamed with IDA, it may not be an accurate
measure. To differentiate between the diagnoses of ACD with and without iron
deficiency, TIBC and sTfR are useful. TIBC is low in ACD, unlike IDA, because
there is ample iron but it is not readily available.51 Additionally, a derived value for
the ratio of sTfR to log ferritin greater than 2 defines ACD with iron deficiency,
whereas a ratio of sTfR to log ferritin less than 1 is typical in ACD without iron
deficiency.53 Therefore, anemia may also be associated with conditions that are
unrelated to micronutrient status.
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1.4

Iron Deficiency in Obesity

Although iron deficiency is generally associated with under-nutrition,
overweight individuals are also at a higher risk of iron deficiency than normalweight individuals. Several studies have shown an inverse relationship between
an individual’s BMI and iron status.54-56

1.4.1 Mechanisms
Potential mechanisms for impaired iron status in the obese state include
decreased dietary intake of iron and increased intake of dietary fat, impaired
intestinal uptake and release of iron, and reduced iron bioavailability due to
inflammation. Through these mechanisms, obesity can influence both true and
functional iron deficiency. To add to the complexity, it is difficult to diagnose iron
deficiency in the setting of obesity due to co-existing inflammation, which
increases the release of acute-phase reactants such as ferritin and thus iron
status may appear artificially high, even in a state of true iron deficiency.57

1.4.1.1 Changes in Dietary Intake
1.4.1.1.1 Dietary Iron Intake
Low dietary intake of iron and high intake of other nutrients in obesity may
contribute to iron deficiency. In a cross-sectional study of 512 adolescents, both
overweight boys and girls had lower iron intakes than their non-overweight
counterparts.58 However, other studies have not confirmed this finding. For
example, in a cross-sectional study of 207 obese and 178 non-obese adults, iron
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deficiency was significantly more prevalent, mean serum iron was lower, and
transferrin saturation was lower among obese compared with non-obese subjects,
despite no differences in dietary iron intake between these groups.

59

In a cross-

sectional survey, the risk of iron deficiency in obese Mexican women and
children was 2-4 times that of normal-weight individuals even though dietary iron
intakes were similar.60 Therefore, it is not conclusive that low iron intake is the
reason for poor iron status in obesity.

1.4.1.1.2 Dietary Fat Intake
Another study investigated the effect of high-fat-diet-induced obesity on
iron metabolism in an animal model of diet-induced obesity. C57BL/6 mice were
placed on a high fat content diet (HFD) or a standard diet (SD) with high
carbohydrate content for eight weeks, and then further randomized to receive or
not receive iron supplementation for an additional two weeks. 29 Mice receiving
the HFD had significantly higher body weight when compared with SD-fed
C57BL/6 mice (P< 0.001). HFD feeding decreased serum and hepatic iron levels,
and response to iron supplementation.29 Duodenal absorption of

59

ferric citrate

was significantly decreased in HFD-fed mice compared to SD-fed mice 60 and
90 minutes after gavage (P<0.05).29 The authors further investigated the
underlying mechanisms of reduced iron absorption in the HFD group by
measuring the mRNA expression of duodenal oxidoreductases, and found that
Dcytb and hephaestin expression were decreased with HFD compared to SD
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with or without iron supplementation.29 This data suggests that interaction
between dietary iron and excess fat in the intestinal lumen may reduce iron
absorption by reducing iron uptake and extrusion by oxidoreductases Dcytb and
hephaestin, respectively.
A human pilot study suggested that the type of dietary fat may also affect
iron absorption. Three male cyclists consumed isoenergetic, isonitrogenous diets
for 28-day periods in a randomized, crossover design in which dietary
carbohydrate, polyunsaturated (PUFA), or saturated fat contributed to roughly 50%
of daily energy intake.61 Fecal iron increased and iron balance (intake – loss)
decreased with the diet high in polyunsaturated fat. Similarly, fecal iron increased
and iron balance decreased with an increase in lineolate intake. 61 Since fecal iron
is an indirect measure of iron absorption, this study suggests that iron absorption
decreases with a diet high in PUFA, particularly linoleic acid. 61 However, a diet
high in saturated fat did not have the same effect. Therefore, larger clinical
studies are needed to determine a relationship between consumption of specific
dietary fats and iron absorption.

1.4.1.2 Obesity-induced Inflammation
Obesity induces low-grade, chronic, systemic inflammation that may
contribute to reduced iron absorption and bioavailability, resulting in true and
functional iron deficiency. This is illustrated by a clinical study of 92
premenopausal Thai women in which fractional iron absorption was negatively

15
correlated with CRP (p<0.001) and BMI (P<0.05) independent of serum ferritin
levels, and CRP was significantly positively correlated with BMI.55 This data
suggests that adiposity-induced inflammation is associated with lower fractional
iron absorption in humans. The authors hypothesized that inflammation-induced
hepcidin was likely causing a decrease in dietary iron absorption by reducing
Fpn1 expression, known as the “Hepcidin Mechanism.”

1.4.1.2.1 Hepcidin Mechanism
Several authors speculate that increased circulating hepcidin in obesity
may be a contributing factor leading to the reduced iron status observed in the
obese population.30,55 In support of this claim, both cell culture and human
studies suggest that hepcidin levels are increased in obesity. The inflammatory
adipokine, leptin, which is secreted by adipose tissue and circulates at levels
proportional to body fat, promoted hepcidin expression in HuH7 human
hepatoma cells in a dose-dependent manner.62 In a human study of 105
candidates for bariatric surgery and 60 control subjects who were stratified
according to BMI category, moderate and severe obesity (BMI > 35 kg/m 2) were
significantly associated with higher serum hepcidin concentration. 63 These data
support the notion of increased hepcidin levels in obesity. Furthermore, in a study
of 60 obese children and 50 control subjects, a direct correlation between
hepcidin and obesity degree (P=0.0015) were observed, as well as inverse
correlations between hepcidin and transferrin saturation (P=0.005) and iron
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absorption (P=0.003).64 This serves as evidence for the link between obesity,
hepcidin, and impairment of iron status.
Another study explored the tissue-specific role of hepcidin in iron
regulation. This study included three groups of obese patients (obese, obese with
diabetes, and obese with nonalcoholic steatohepatitis [NASH]), control adipose
tissue from lean females, and control liver samples which were histologically
normal and non-inflamed from males and females. These patients were
investigated to determine the possible role of hepcidin in severe obesity.65 Low
transferrin saturation was observed in 68% of the patients and 24% of these
patients presented with anemia.65 Hepcidin mRNA and protein levels in
subcutaneous adipose tissue (SAT) were significantly enhanced in all obese
conditions compared to control adipose tissue samples, and SAT hepcidin mRNA
expression was correlated with the BMI of the patients; there was no effect of
diabetes or NASH on hepcidin expression levels in liver or adipose tissue. Also,
the hepcidin mRNA concentration in adipose tissue was related to the expression
of inflammatory markers CRP and IL-6. However, hepcidin expression in adipose
tissue was similar in iron-depleted and iron non-depleted obese groups,
suggesting that adipose-derived hepcidin may play a minimal role in iron
mobilization in obesity.65 Interestingly, liver biopsy showed that hepatic hepcidin
mRNA expression levels in obese individuals were not significantly different from
those of control liver samples. Still, there was a negative correlation found
between liver, but not adipose tissue, hepcidin expression and serum transferrin
saturation in the obese, suggesting that the effects of hepcidin may be tissue
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specific.65 Thus, further studies are needed to determine the role of adipose
versus hepatic production of hepcidin and adverse effects on iron homeostasis in
obesity.65

1.4.1.2.2 Hepcidin-Independent Mechanism
Inflammation, through mediators that are separate from hepcidin
production, may induce iron sequestration in adipose tissue and liver, thereby
contributing to iron deficiency in obesity. mRNA expression and circulating
concentrations of

lipocalin-2 in adipose and hepatic tissue were significantly

increased in db/db leptin receptor deficient, obese mice compared with their lean
littermates (P<0.001).30,66 Lipocalin-2 is an iron-binding protein that is
upregulated by inflammation and may promote sequestration of iron during
infections to limit bacterial growth.29,62 Therefore, inflammation may induce
functional iron deficiency by adipose and hepatic sequestration of iron.

1.4.1.3 Summary of Mechanisms Responsible for Iron Deficiency in Obesity
In summary, obesity may increase risk for iron deficiency by 1) reducing
iron absorption in the intestine due to high consumption of fat, 2) decreasing iron
mobilization from the intestine and peripheral tissue via hepcidin which is induced
by inflammation, and 3) increasing the sequestration of iron in adipose and
hepatic tissues via inflammation-induced upregulation of lipocalin-2.
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1.5

Bariatric Surgery for the Treatment of Obesity

Bariatric surgery is growing in popularity as a treatment to induce weight
loss in patients who are moderately (body mass index, BMI ≥ 35 kg/m 2) and
severely (BMI ≥ 40 kg/m2) obese. The most recent 2013 guidelines for the
management of overweight and obesity in adults, endorsed by the American
Heart Association, the American College of Cardiology, and The Obesity Society,
strongly recommend that adults with a BMI ≥ 40 or BMI ≥ 35 with obesity-related
comorbid conditions, who are motivated to lose weight and have not responded
to behavioral treatment, be referred to an experienced bariatric surgeon for
evaluation.67 In addition, bariatric surgery has been implicated in the amelioration
of comorbid cardiometabolic diseases.13,68-73 Bariatric surgery may also decrease
risk of mechanical (arthritis and osteoarthritis, respiratory diseases and sleep
apnea) and psychosocial (depression and eating disorders) complications of
obesity.
Bariatric surgery induces weight loss by altering the gastrointestinal tract
to promote food restriction and/or malabsorption. Therefore, bariatric surgery
promotes deficiencies in various micronutrients including iron.68 As a result,
obese patients who choose to undergo bariatric surgery may experience the
‘double burden’ of iron deficiency caused by pre-existing obesity, as well as
changes in dietary intake, nutrient absorption, and inflammation following
bariatric surgery. The risk of iron deficiency varies with each type of surgery and
is related to the anatomical alterations that are made. The anatomical
descriptions of the various types of bariatric surgery have been extensively
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reviewed and are shown in figure 1.2.68 The following is a brief overview of the
surgeries.

Figure 1.2 Anatomies of Bariatric Procedures. (A) Laparoscopic adjustable
gastric banding. (B) Roux-en-y gastric bypass. (C) Sleeve gastrectomy. (D)
Biliopancreatic diversion with duodenal switch.
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1.5.1 Restrictive Bariatric Surgeries
Restrictive procedures achieve weight loss by reducing stomach volume
or absorptive capacity. The two currently-performed restrictive procedures are
the adjustable gastric banding (AGB) and sleeve gastrectomy (SG) procedures.
Recent 2011 data show that the former is decreasing, while the latter is growing,
in popularity.74

1.5.1.1 Adjustable Gastric Banding (AGB)
In the AGB procedure (figure 1.2a), a band is placed around the proximal
stomach, encompassing the upper portion of the fundus and creating a
temporary holding pouch of 30 mL. When food is ingested, the pouch expands
and creates intraluminal pressure, which triggers satiety signals.75 This surgery
requires that a trained medical professional periodically tighten the band around
the stomach to maintain the feeling of fullness. Routine band adjustment largely
determines the effectiveness of this procedure. If the flow of food is obstructed by
the narrowness of the band, nutritional complications, such as reflux, nausea,
and/or vomiting may occur. AGB is associated with reduced tolerance for coursetextured foods, which may lead to the avoidance of red meats and fibrous fruits
and vegetables.76-78
1.5.1.2 Sleeve Gastrectomy (SG)
In the SG procedure (figure 1.2c), the larger curvature of the stomach is
dissected, leaving a narrow vertical tube that can hold a volume of 150 mL.
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Similar to AGB, SG achieves earlier satiety following a meal. 68,79 In addition to
reducing stomach volume, increased satiety may occur by decreases in the
appetitive hormone ghrelin and increases in the satiety hormone polypeptide YY
that have been observed following SG.80 Also, SG may decrease gastric
emptying half-time, which is the time required by the stomach to empty 50% of
the ingested meal, as well as small bowel transit time,81 thus limiting the
digestion, absorption, and bioavailability of some nutrients. 68

1.5.2 Combined Restrictive and Malabsorptive Bariatric Procedures
Malabsorptive procedures alter the flow of food to limit contact with
pancreatic secretions and/or bypass absorptive regions of the intestine in order
to limit nutrient absorption.68

1.5.2.1 Roux-en-Y Gastric Bypass (RYGB)
The roux-en-y gastric bypass (RYGB, figure 1.2b) procedure is the most
common procedure in the United States82 and combines restrictive and
malabsorptive mechanisms. In the RYGB procedure, the stomach is reduced to a
volume of 20-30 mL, and the food bolus is rerouted to the distal jejunum via an
anastomosis connection.83 Although malabsorption of proteins and fats occurs at
least initially after RYGB, restricted dietary intake plays a much larger role in the
reduction of energy intake.84 Weight loss associated with alterations in the
secretion of appetitive and satiety gastrointestinal hormones may be even more

22
pronounced in RYGB compared to SG, as RYGB induces decreased fasting
ghrelin concentrations, as well as increased postprandial PYY and glucagon-like
peptide 1 (satiety hormone) concentrations.85 In addition, shunting of undigested
food, particularly if high in simple carbohydrates or fat, directly to the lower
jejunum, which serves as the common channel, can produce an osmotic
imbalance that triggers severe gastrointestinal symptoms such as bloating,
nausea, vomiting, flatulence, and diarrhea, collectively known as dumping
syndrome. Thus, following RYGB, patients develop food intolerances and avoid
nutrient-dense foods such as meat, milk, and foods high in fiber.76,86

1.5.2.2 Biliopancreatic Diversion (BPD)
The biliopancreatic diversion (BPD) and the more recent version, the
biliopancreatic diversion with duodenal switch (BPD-DS, figure 1.2d), are
primarily malabsorptive procedures, although their popularity in the United States
and other countries is low.74 In the BPD-DS, the stomach is resected as is done
for the SG, and then the intestine is divided at the duodenum after the pyloric
sphincter in the proximal small intestine, and again in the distal intestine, creating
biliopancreatic and alimentary limbs, respectively. The alimentary limb is brought
up and connected to the duodenum, causing food leaving the stomach to bypass
most of the small intestine. Thus, immediately following exit from the stomach,
the food bolus is diverted and then rejoined with the biliary and pancreatic juices
in a common channel that begins at the ileum.68 This procedure achieves greater
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weight loss than RYGB, but is associated with more early complications and
slightly higher perioperative mortality.87

1.5.3 Consequences of Bariatric Surgery
Poor nutritional outcomes have been associated with all weight loss
surgeries. These may include macro- and micronutrient deficiencies as well as
weight regain.68 In patients who experience weight regain, chronic obesity-related
inflammation will likely persist following surgery. Notably, in the years following
surgery the intestine adapts to improve macronutrient absorption,88 however the
effect of gut adaptation on micronutrients has not been clearly demonstrated.
Nutrient deficiencies may be a result of decreased dietary intake or retention of
food following surgery, reduced absorption, or decreased bioavailability.

1.5.3.1 Iron Deficiency
Iron deficiency has been well-documented following bariatric surgery
(postoperative prevalence: 15-54%8-12), but it is difficult to diagnose and treat due
to its multifactorial etiology. This is partly because deficiencies in other nutrients
may co-exist with deficiency in iron following surgery, and also that the signs and
symptoms of iron deficiency, such as anemia, are shared with other nutrient
deficiencies.11
Of the common bariatric surgeries, the frequency of iron deficiency is
highest in RYGB.89-92 In a large cohort study (N=21,345), the prevalence of iron
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deficiency in RYGB patients steadily increased from the pre-bariatric surgical
period through the post-bariatric surgical periods; the prevalence was 5% presurgery, 10% at 0-12 months, 13% at 13-24 months, and 21% at 25-36 months.93
Similarly, clinical records of 30 patients who underwent laparoscopic RYGB
surgery between July 2003 and January 2005 showed that the number of
patients who presented with iron deficiency increased from 6.6% before surgery
to 40% at 2 years and 54.5% at 3 years following surgery.11 These findings are
consistent with others that show exacerbation of iron deficiency following
RYGB.8,10,11,68,94-97 The range in estimates may be attributed to differences in the
indices used, the period of time evaluated post-surgery, and the occurrence of
iron deficiency without symptoms.68 However, symptomatic manifestations of iron
deficiency after RYGB include hematological disorders such as chronic anemia
and even pica, a condition associated with iron deficiency inducing unusual
cravings for ice, cornstarch, clay, and other substances. 89 Premenopausal
women who undergo RYGB have an increased risk of iron deficiency due to
regular blood loss during menses.68 In order to prevent iron deficiency and its
disabling symptoms following surgery, it is important to elucidate the
mechanisms by which iron status is reduced.

1.6

Mechanisms for Iron Deficiency following Bariatric Surgery

Changes in dietary intake, absorption, and bioavailability, due to
mechanical alterations that are inherent to each surgical procedure, contribute to
iron deficiency following bariatric surgery.
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1.6.1 Changes in Dietary Intake
1.6.1.1 Iron intake
Dietary intake of iron was reported to be lower than the recommended
amount

following

sleeve

gastrectomy

and

roux-en-y

gastric

bypass

surgeries.68,94,98 Decreased iron intake and retention may be related to
gastrointestinal distress, including intolerance of iron-containing foods, as well as
reduced availability of other nutrients whose levels are also decreased postsurgery. Some evidence suggests that intake of meat, a good source of
bioavailable heme iron, is reduced, which contributes to iron deficiency after
bypass surgery

68,89

In one study, 27 out of 69 patients who had received gastric

bypass experienced emesis (vomiting) after consuming fibrous meats.99 In
another study, 50% of bypass patients experienced chronic meat intolerance
after surgery.100 However, in a randomized control trial comparing bypass with
banded patients, only the bypass patients were iron deficient, despite having
better tolerance for eating red meat.91 Therefore, low meat intake alone may not
explain iron deficiency in bariatric surgery patients.

1.6.1.2 Intake of Nutrients Related to Iron
Dietary intake of other nutrients, such as copper, is also important as
these nutrients may enhance or inhibit iron absorption and metabolism. Copper is
a component of the multicopper ferroxidase hephaestin, which catalyzes the
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conversion of Fe2+ to Fe3+ so that it can be transported by transferrin into
circulation.39 Notably, copper deficiency following bariatric surgery has been
reported to have a prevalence ranging from 10 to 15% and an incidence ranging
from 4 to 18%.68 Copper deficiency following surgery may result from insufficient
copper in micronutrient supplementation and malabsorption of copper in the
duodenum and proximal jejunum.68 Therefore, malnutrition in copper may
contribute to iron deficiency in bariatric surgery patients.

1.6.2 Reduced Iron Absorption
Mechanisms related to anatomical alterations following bariatric surgery
may contribute to reduced iron absorption and bioavailability. Heme and nonheme iron absorption are reduced after SG and RYGB.101,102

1.6.2.1 Diminished Gastric Acid Secretion
Diminished gastric acid secretion and exclusion of the duodenum may
contribute to iron malabsorption. In malabsorptive procedures the antrum is
separated from the proximal gastric pouch, resulting in diminished gastric acid
secretion. A longitudinal study showed a significant post-surgical decrease in
acid secretion in eight patients who underwent gastric bypass. 89,103 Reduced acid
secretion hinders the reduction of ferric iron and ultimately absorption of ferrous
iron in the duodenum.89 In support of this mechanism, banding procedures, which
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maintain gastrointestinal continuity, have lower rates of iron deficiency than
bypass procedures.89,104,105

1.6.2.2 Duodenal Exclusion
Excluding the duodenum from digestive continuity may also contribute to
decreased iron absorption. Most absorption of non-heme and highly bioavailable
heme iron occurs across duodenal enterocytes.28 Therefore, it is not surprising
that decreasing the amount of duodenal absorptive surface area may diminish
iron absorption following malabsorptive procedures. In support of this point,
patients undergoing BPD-DS, which preserves some proximal duodenal function
compared to BPD, may experience less iron deficiency.89 BPD-DS patients had
significantly higher serum ferritin levels than BPD patients. 89,106 However, a
recent study comparing BPD and BPD-DS found no significant difference in
serum iron levels.89,107 Additional information is needed to draw conclusions
because serum iron is not a good indicator of iron status.

1.6.2.3 Decreased Duodenal Absorptive Capacity
In addition to decreasing duodenal absorptive capacity, malabsorptive
procedures delay interaction between pancreatic enzymes and biliary secretions
and the food bolus until the common channel. This has a pronounced adverse
effect on heme iron absorption, as biliopancreatic secretions are necessary for
proteolytic digestion of myoglobin and hemoglobin, and ultimately the release of
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heme that is available for absorption.89,108 Therefore, incomplete digestion of
heme iron may exacerbate iron malabsorption.

1.6.3 Inflammation
1.6.3.1 Bacterial Overgrowth
Inflammation

caused

bioavailability

via

Malabsorptive

bariatric

by

mechanisms
surgery

bacterial
similar
may

overgrowth
to

induce

may

obesity-related
bacterial

reduce

iron

inflammation.

overgrowth

and

inflammation in the functional and remnant stomach.82 In a prospective
observational study of 35 RYGB patients who had predominantly normal gastric
endoscopic findings before surgery, 74.3% developed various types of gastritis,
or inflamed lining of the stomach, almost exclusively in the excluded stomach. 109
Also, in post-RYGB subjects, high microbial counts were detected in 59.5% of
samples from the functional gastric pouch and 18.9% of samples from the
excluded reservoir.110 Infection by Helicobacter pylori was correlated with
bacterial overgrowth.110 Therefore, inflammation due to bacterial overgrowth may
contribute to iron deficiency following bariatric surgery.

1.6.3.2 The Inflammation Discrepancy
A paradoxical impact of bariatric surgery is that although it appears to
impair iron status, it also promotes long-term weight loss, thereby ameliorating
chronic inflammation of obesity, and thus may improve iron status over time.

29
Following bariatric surgery, reductions in BMI, CRP, IL-6, and orosomucoid are
well-documented.111,112,113 One study showed a significant increase in transferrin
saturation at six months following surgery, which the authors attributed to the
reduction of inflammation, as CRP and orosomucoid were inversely correlated
with transferrin saturation before and after surgery.113 This data suggests that
bariatric surgery-induced weight loss is associated with reduction of inflammation
and improvement in functional iron status in these patients. However, this finding
is in contrast to the findings of several studies that show exacerbation of iron
deficiency up to three years following RYGB.11,93 Therefore, there may be other
factors that may explain the discrepancy, such as the time that has elapsed since
surgery.

1.7

Research Questions

With the increasing trend of severe obesity, there is an increase in the
number of bariatric procedures performed worldwide.114 RYGB is the most
commonly performed bariatric procedure.114 A high prevalence of iron deficiency
is documented following RYGB (10-45%).8,10,11,94-97 Hemoglobin concentrations
were significantly lower in patients receiving gastric bypass than in restrictive
bariatric surgeries115 and prevalence of anemia as high as 64% has been
reported following RYGB.11,96,115-119 A well-established mechanism for iron
deficiency following RYGB shown by Ruz et al is reduced iron absorption. 101,102
Other suggested mechanisms include reduced intake of iron and other nutrients
related to iron homeostasis, and persisting obesity-induced or other sources of
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inflammation. Chapter 2 describes studies in which we document the high
prevalence of iron deficiency and the associated clinical manifestation of anemia
following RYGB as well as explore some mechanisms responsible. Our overall
objective was to describe iron homeostasis following RYGB by using
comprehensive screening approach to assess micronutrient status, dietary intake,
and anemia in RYGB patients. The first aim was to conduct a comprehensive
screening of nutrients involved in iron homeostasis in RYGB patients. We
hypothesized that iron deficiency occurs in combination with other nutrient
deficiencies. The second aim was to determine the contribution of dietary intake
to the micronutrient profile of RYGB patients. We hypothesized that low intake of
iron and intake of nutrients involved in iron homeostasis from diet and
supplements contributes to malnutrition in iron following RYGB. The third aim
was to describe associations between anemia and nutritional status in RYGB
patients. We hypothesized that anemia is associated with iron deficiency as well
as deficiencies in other nutrients following RYGB.
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2.2

Abstract

Roux-en-Y gastric bypass surgery (RYGB) is effective for weight loss, but
is commonly associated with iron deficiency and its clinical manifestation, anemia.
Diagnosing iron deficiency is complex because iron status depends on other
nutrients; additionally, anemia following surgery is not specifically due to
deficiency in iron, as it can be due to deficiencies in other nutrients including zinc,
copper, vitamin B6, folate, and vitamin B12. In patients who have undergone
RYGB, our aims were to 1) conduct a comprehensive assessment of nutrients
involved in iron homeostasis, 2) determine the contribution of dietary intake to
iron deficiency, and 3) describe associations between anemia and nutritional
status of iron and other nutrients. Systemic measures of hemoglobin, ferritin,
serum transferrin receptor (sTfR), total iron binding capacity (TIBC), copper (Cu),
vitamins B6 and B12, folate, zinc (Zn), and C-reactive protein (CRP) were
determined using reference methods. Iron deficiency equaled having ≥ 2
abnormalities in: ferritin, sTfR, sTfR:ferritin, or TIBC. Ferritin, a measure of iron
stores, was defined as normal (ferritin ≥ 20 mcg/L) or low (ferritin < 20 mcg/L).
Statistics included prevalence, mean ± standard error of the mean (s.e.m.) for
normally-distributed data, median ± semi-interquartile range for skewed data
(indicated with an asterisk [*]), frequency tables, t-tests (independent, by group),
correlations, and general linear models (significant if p < 0.05). Subjects (N=70)
were 91% female, age 49 ± 1 years, *4 ± 2 years post surgery, and 79%
Caucasian. Fifty-six percent of the total population and 96% of the subpopulation
with anemia (N=26) presented with deficiencies related to iron nutriture, including
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deficiencies in iron, zinc, copper, vitamin B6, folate, and vitamin B12. The most
prevalent nutrient deficiencies in the total population and the subpopulation with
anemia were iron and zinc; prevalence of iron and zinc deficiency in the total
population was 24.3% and 20.0%, respectively, and prevalence of iron and zinc
deficiency in the subpopulation with anemia was 46.2% and 23.1%, respectively.
Participants in the total population and the subpopulation with anemia were also
deficient in copper, vitamin B6, vitamin B12, and folate (11.5% and 26.9%,
respectively). In the total population, iron and zinc deficiency occurred in isolation
and also in combination with other nutrient deficiencies; all other nutrient
deficiencies occurred in combination. In the subpopulation with anemia, only iron
deficiency occurred in isolation. The dietary intake of the study population
exceeded the RDAs for all nutrients assessed. In addition, patients with low
ferritin concentrations consumed lower total energy (p= 0.009), fat (p= 0.026),
protein (p=0.013), and animal protein (p=0.023), compared to patients with
normal ferritin concentrations. Dietary intake of heme iron was correlated with
years post-RYGB surgery (r=0.67, p<0.05). In conclusion, in a community-based
surveillance of RYGB patients we found that, more often than not, RYGB patients
presented with micronutrient deficiencies related to iron nutriture; this includes
deficiencies in iron, copper, zinc, vitamin B6, folate, and vitamin B12. It was more
likely for multiple deficiencies to occur simultaneously than for deficiencies to
occur alone. In addition, there was a high prevalence of anemia, a clinical
manifestation of deficiencies in these nutrients. Implications of these findings are
that clinicians who evaluate post-RYGB patients, especially patients who present
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with known symptoms or manifestations of iron deficiency, should also screen
patients for deficiencies in copper, zinc, vitamin B 6, folate, and vitamin B12, as
these

deficiencies

are

also

prevalent

following

surgery,

may

occur

simultaneously with iron deficiency, and are also implicated in anemia. Based on
our findings that RYGB patients who have more favorable iron stores consume
more energy, fat, and protein than patients with low iron stores, increasing
protein intake following surgery may improve iron status; although, increasing
consumption of fat may have detrimental effects on weight regain in the RYGB
population. Findings of this study may be used to enhance prophylactic
measures and treatments for iron deficiency following RYGB.

2.3

Introduction

The rate of obesity (BMI > 30 kg/m2) is increasing; in particular, there is an
increasing trend in the severely obese category (BMI ≥ 40 kg/m2).2 Bariatric
surgery is an effective treatment for weight loss, as well as the improvement or
resolution of obesity-related comorbidities including diabetes, hyperlipidemia,
hypertension, and obstructive sleep apnea.120 Therefore, it is not surprising that
as the number of severely obese persons increases, there is a parallel increase
in the number of bariatric procedures performed worldwide.114 The roux-en-y
gastric bypass (RYGB) procedure is the most commonly performed bariatric
procedure in the United States82 and combines restrictive and malabsorptive
mechanisms that promote weight loss. In the RYGB procedure, the stomach is
reduced to a volume of 20-30 mL, and the food bolus is rerouted to the distal
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jejunum via an anastomosis connection83; therefore, patients who undergo RYGB
are vulnerable to nutrient deficiencies due to restricted food intake and
malabsorption of nutrients.
There is a high prevalence of iron deficiency in obese individuals who are
candidates for bariatric surgery (28%-35%)5-7 and following RYGB (1045%).8,10,11,94-97 Iron deficiency is the most common and widespread nutritional
disorder in the world, and the only nutrient deficiency that is significantly
prevalent in industrialized nations.13,14 Iron deficiency is associated with
increased infant mortality and perinatal risks for mothers and neonates, and
adversely affects cognitive performance, behavior, and physical growth of infants
and adolescents. Iron deficiency also impairs immune status, increases morbidity
from infections, and reduces physical capacity and work performance in all age
groups.13 Severe iron deficiency is associated with low blood concentrations of
hemoglobin, and is termed iron deficiency anemia (IDA).13 Reported mechanisms
that may contribute to the high prevalence of iron deficiency following RYGB
include reduced heme and non-heme iron absorption101 and reduced dietary iron
intake.94,98
Assessment of iron status is complex. First, iron status depends on other
nutrients, such as copper- which is involved in iron absorption via the enzyme
hephaestin, vitamin B6 and zinc- which are involved in heme synthesis, and
vitamin B12 and folate- which are needed for blood cell differentiation. Second, it
is possible that deficiencies in multiple nutrients which impact iron status may
occur simultaneously in patients who have undergone gastric bypass, although
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there is a lack of evidence in the literature. Finally, the widely known clinical
manifestation of iron deficiency, anemia (low hemoglobin), adds to the complexity
of diagnosing iron deficiency. Anemia is observed after RYGB with a prevalence
as high as 64%.11,94,113-117 However, anemia following surgery is not specific to
deficiency in iron alone, as it can be due to deficiencies in other nutrients
including copper, folate, vitamin B12, zinc, and vitamin B6.
To our knowledge, no one has explored the reasons for and
consequences of the poor iron homeostasis observed following RYGB by
describing micronutrient status, dietary intake, and anemia associated with the
various nutrients implicated in iron nutriture. In patients who have undergone
RYGB, our aims were to 1) conduct a comprehensive assessment of nutrients
involved in iron homeostasis, 2) determine the contribution of dietary intake to
iron deficiency, and 3) describe associations between anemia and nutritional
status of iron and other nutrients. Findings of this study will be significant as they
may be used to enhance prophylactic measures and treatments for iron
deficiency following RYGB.

2.4

Patients and Methods

We used a marketing database to obtain addresses in the Greater
Lafayette, IN community and recruited participants by mailing information about
the study. Recruiting participants from the community and randomly selecting
addresses afforded us a representative sample of bariatric surgery patients who
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obtained their surgical procedures at various clinics and who had various lengths
of elapsed time since surgery.

2.4.1 Study Population
The study began May of 2012. During recruitment, participants were prescreened by telephone. They were eligible for screening if they underwent RYGB
at least 6 months prior, and were 18-65 years of age. After August 2013, we
added the additional criterion that participants must be currently experiencing
anemia, and we also began to administer a three-day food record to each eligible
participant to complete prior to the screening visit.

2.4.2 Metabolic Measures
We did a comprehensive screening of nutrients related to iron
homeostasis. Plasma samples were obtained at screening and stored at -80°C.
Ceruloplasmin activity and serum transferrin receptor were measured in-house.
Ceruloplasmin activity was measured using the oxidase method. 121 The
coefficients of variation for the intra- and inter-assay variability were 3.6% and
3.8%, respectively. Soluble serum transferrin receptor was measured using the
enzyme-linked immunosorbent assay (R&D Systems, Minneapolis, MN, USA).
Copper, ferritin, zinc, vitamins B1, B6, B12, folate, hemoglobin, TIBC, and Creactive protein were commercially measured by Mid America Clinical
Laboratories (MACL), Indianapolis, IN, USA. Serum copper and zinc were
measured using inductively coupled plasma mass spectrometry (ICP/MS).
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Vitamin B1 from whole blood and serum vitamin B6 were measured using liquid
chromatography coupled to tandem mass spectrometry (LC-MS/MS). Serum
ferritin was measured using a Chemiluminescent Microparticle Immunoassay
(CMIA). Serum vitamin B12 and folate were measured using chemiluminescence.
Siemens Advia 2120i instrumentation was used by MACL to perform hemoglobin
analysis. TIBC was measured using the tripyridyltriazine/ferine method. CRP was
measured using the turbidimetric latex method.
Subjects were found to be deficient in iron if they met at least two of the
following four conditions: TIBC > 370 mcg/dL (cutoff determined by MACL),
serum ferritin < 20 mcg/L,122,123 serum transferrin receptor (sTfR) > 28.1 nmol/L,
sTfR:ferritin ratio > 500.122 Subjects were found to be anemic if hemoglobin < 12
g/dL in menstruating women and hemoglobin < 13 g/dL in men and postmenopausal women.13 Deficiencies in other nutrients were defined as copper
(serum copper < 70 mcg/dL determined by MACL; ceruloplasmin < 62.5 U/L121),
zinc < 60 mcg/dL, vitamin B6 < 2.1 ng/mL, folate <5.4 ng/mL and vitamin B12 <
220 pg/mL. Inflammation, measured by cardio C reactive protein (CRP), was
abnormally high if > 3.1 mg/L (cutoffs determined by MACL).

2.4.3 Dietary Analysis
Nine participants completed three-day food records, for which we
performed dietary analysis using Nutrition Data System for Research (NDSR);
software (University of Minnesota, Minneapolis, MN, USA). The daily intake of
macro- and various micronutrients was determined (Table 2.3). Dietary heme
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iron was calculated by multiplying the number 0.4 by the total iron content of all
meat items.

2.4.4 Statistical Analysis
The statistical software STATISTICA (StatSoft Inc., Tulsa, OK, USA) was
used for analysis. Descriptive statistics were assessed using parametric tests
and expressed as mean ± standard error of the mean (s.e.m.) for normally
distributed data and median ± semi-interquartile range for skewed data. Values
presented as median ± semi-interquartile range are indicated with an asterisk (*).
Prevalence of micronutrient deficiencies were determined and defined as the
number of cases of each micronutrient deficiency; the denominator was 70
subjects for the total population, 26 subjects for the population with anemia, and
nine subjects for the population with dietary records. Differences between
categorical groups were determined using independent t-tests; associations
between nutrient status and continuous variables (such as dietary intake and
blood concentrations of micronutrients) were determined using independent ttests, by group. Pearson correlations between continuous variables were
performed. We had the capability of using general linear models to determine
potential interactions between covariates if we found significant correlations
between variables; however, we found no correlations between variables of
interest. Differences in prevalence of deficiency between populations were
determined using chi-square analysis. Significance was defined as p < 0.05.
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2.5

Results

2.5.1 Population Characteristics
Table 2.1 shows the population characteristics for the total population, the
subpopulation with anemia, and the subpopulation with completed three-day food
records. In the total population, 70 eligible patients were assessed. The
population was 91% female, 79% Caucasian and 14% African American. At the
time of screening, subjects were 49.4 ± 0.9 years of age and were *4 ± 2 years
post-RYGB surgery. The average BMI in the total population was *28.9 ± 2.7
kg/m2. Fifty-one percent of the subjects in the total population reported taking
multivitamin/multimineral supplements and 10% reported not taking these
supplements; thirty-nine percent of the total population did not provide this
information.
The subpopulation with anemia included 26 RYGB patients. The
population was 100% female, 75% Caucasian and 25% African American. At the
time of screening, subjects were 50.3 ± 1.2 years of age and were *4 ± 2 years
post-RYGB surgery. The average BMI in the population with anemia was *26.4 ±
2.5 kg/m2. Fifty percent of the subjects in the population with anemia reported
taking multivitamins and 12% reported not taking multivitamins; thirty-eight
percent of the subpopulation with anemia did not provide this information.
The subpopulation with three-day food records included nine RYGB
patients. The population was 89% female and 100% Caucasian. At the time of
screening, subjects were 48.0 ± 2.6 years of age and 5.4 ± 1.7 years post-RYGB
surgery. The average BMI in the population with dietary records was *26.5 ± 2.7
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kg/m2. Seventy-eight percent of the subjects in the population with dietary
records reported taking multivitamins and 22% reported not taking multivitamins.

2.5.2 Nutrient Deficiencies
Table 2.2 shows the prevalence of deficiency for nutrients involved in iron
homeostasis in the total population, the subpopulation with anemia, and the
subpopulation with dietary records. In 55.7% of the total population, we found
deficiencies in nutrients related to iron nutriture. Prevalence of deficiency in the
total population for iron (Fe), zinc (Zn), copper (Cu), vitamin B6 (B6), folate (Fol),
and vitamin B12 (B12) from highest to lowest were: Fe= 24.3%, Zn= 20.0%, B6=
4.3%, Cu= 2.9%, B12= 2.9% and Fol= 1.4%. In 44.3% of the total population we
did not find deficiencies related to iron homeostasis.
Prevalence of anemia in the total population was 37.1%. In 96.2% of the
subpopulation with anemia, we found deficiencies in nutrients related to iron
nutriture. Prevalence of deficiencies in the subpopulation with anemia from
highest to lowest were: Fe= 46.2%, Zn= 23.1%, Cu= 7.7%, B6= 7.7%, B12= 7.7%,
and Fol= 3.8%. In 3.8% of the participants with anemia we did not find
deficiencies related to iron homeostasis. There was a significantly higher number
of participants with iron deficiency in the subpopulation with anemia compared to
the total population (p= 0.04). There was no significant difference in the number
of participants with zinc, copper, vitamin B6, folate, or vitamin B12 deficiencies
between the total population and the subpopulation with anemia.
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Prevalence of deficiencies in the subpopulation with three-day food
records from highest to lowest were: Fe= 22.2%, Zn= 11.1%, Cu= 11.1%, B6=
0%, Fol= 0%, and B12= 0%. Prevalence of anemia in the subpopulation with
three-day food records was 44.4%. In 55.5% of the population with dietary
records we did not find deficiencies related to iron homeostasis.
Figure 2.1 shows that patients in the total population experienced isolated
deficiencies (deficiencies occurring alone) and combined deficiencies (multiple
deficiencies occurring simultaneously) in nutrients involved in iron homeostasis.
In the total population, iron and zinc deficiency occurred in isolation as well as in
combination with other micronutrient deficiencies. Iron deficiency occurred in
isolation (prevalence 19%) and in combination with deficiencies in zinc and
vitamin B12 (prevalence 6%). Zinc deficiency occurred in isolation (prevalence 7%)
or combined with deficiencies in other nutrients, including iron, copper, vitamin B 6,
folate, and vitamin B12 (prevalence 13%). Deficiencies in the other nutrients
(copper, vitamin B6, folate, and vitamin B12) occurred in combination with other
nutrient deficiencies only.
Figure 2.2 shows that patients in the population with anemia experienced
isolated and combined deficiencies in nutrients implicated in iron homeostasis
and anemia. There was a higher prevalence of deficiencies in nutrients other
than iron, but that were still involved in iron homeostasis and metabolism, than
iron deficiency. Participants with anemia presented with isolated iron deficiency
(prevalence 35%), as well as iron deficiency combined with deficiencies in zinc
and vitamin B12 (prevalence 12%). Nutrient deficiencies other than iron deficiency
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were present in combination only (prevalence 49%); nutrients included zinc,
vitamin B6, folate, vitamin B12 and copper. In 4% of the population with anemia
(one participant), we did not detect any deficiencies in nutrients related to iron
nutriture.
Normal or deficient status of iron, zinc, copper, vitamin B 6, folate, or
vitamin B12 was not associated with the number of years since surgery.
Concentration of iron, zinc, copper, vitamin B6, folate, or vitamin B12 was not
correlated with the number of years since surgery.

2.5.3 Blood Cell Size in Participants with Anemia
Within the subpopulation with anemia, 15% of participants presented with
microcytic anemia (MCV < 78 fL) and 85% presented with normocytic anemia
(MCV 78-100 fL). Of the four participants with microcytic anemia, one was
deficient in iron only, one was deficient in zinc only, one was deficient in iron and
zinc only, and in one patient we did not assess micronutrient deficiencies.

2.5.4 Dietary Intake
The average intakes of macronutrients, as well as micronutrients that
impact iron absorption and homeostasis are shown in Table 2.3. On average
patients reported a daily intake of total energy= 1650.4 ± 605.1 kcal, total fat=
66.5 ± 10.2 g, total protein= 77.9 ± 9.8 g, animal protein= 57.8 ± 8.6 g, and total
carbohydrate= 189.8 ± 28.9 g. Daily micronutrient intake averaged total iron=
41.8 ± 18.2 mg, heme iron= 0.85 ± 0.18 mg, non-heme iron= 40.9 ± 18.3 mg,
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copper= 2.6 ± 0.9 mg, zinc= 19.7 ± 5.3 mg, calcium= 1407.8 ± 341.0 mg, vitamin
C= 108.0 ± 30.6 mg, vitamin B6= 3.1 ± 0.8 mg, folate= 594.2 ± 169.1 mcg, and
vitamin B12= 119.8 ± 112.5 mcg. This population, on average, exceeded the
RDAs for all nutrients assessed, including vitamin C which enhances iron
absorption, and calcium which inhibits iron absorption. However, we did not find
significant associations or correlations between micronutrient intake and iron
status.
We found associations between intake of macronutrients and iron status.
Total energy intake (p= 0.009), as well as fat (p= 0.026), protein (p=0.013), and
animal protein (p=0.023), was higher in subjects with normal compared to low
ferritin status (Figure 2.3). We did not find significant associations between iron
status (overall iron deficiency status, and status of iron deficiency measured by
ferritin, TIBC, sTfR and sTfR:ferritin ratio) or anemia, and dietary intake of total
iron, heme iron, or non-heme iron (data not shown). Dietary heme iron intake
was correlated with years post-RYGB surgery (r=0.67, p<0.05; figure 2.4); for
each increase in years post surgery, dietary iron intake increased by 0.67 ± 0.28
mg. There was no association between meat servings and iron status. There
were no associations between intake of other micronutrients or macronutrients
and time following surgery.

2.6

Discussion

In summary, our main findings were that following RYGB, more than half
of the patient population presented with deficiencies related to iron nutriture,
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including deficiencies in iron, zinc, copper, vitamin B6, folate, and vitamin B12;
prevalence of deficiency was not related to the number of years since surgery. Of
importance, simultaneous deficiencies were common. Notably, of the isolated
deficiencies, iron was most prevalent. Similarly, patients with anemia had
isolated iron deficiency as well as simultaneous deficiencies in iron, zinc, copper,
vitamin B6, folate, and vitamin B12; deficiencies in nutrients other than iron were
more common than isolated iron deficiency in the subpopulation with anemia. In
addition, RYGB patients, on average, exceeded the RDAs for nutrients involved
in iron homeostasis, as well as nutrients known to inhibit iron absorption;
however, there was no association between the intake of micronutrients and iron
status or anemia. RYGB patients with low iron stores (indicated by ferritin
concentrations) consumed less total energy, fat, protein, and animal protein than
patients with normal iron stores, suggesting that the intake of macronutrients had
a greater impact on iron status than the intake of micronutrients. Finally, dietary
heme iron intake increased with time following RYGB surgery, suggesting that
gastric bypass patients consume more meat further out from surgery.
Consistent with recent literature, we have documented deficiencies in
iron,8,10,11,94-97,124 zinc,125 copper,126 vitamin B12,124 folate,124 and vitamin B6127
following RYGB. Compared to recent studies, most of which have followed
RYGB surgery cohorts for up to two years post-surgery,124-126 our findings show
the prevalence of deficiencies in nutrients implicated in iron homeostasis in
RYGB patients who are, on average, five years post-surgery. Since we
measured patients who were further out from surgery, our reported prevalence
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of deficiency may be lower, compared to other studies, for nutrients such as
folate= 15%,124 vitamin B12= 50%,124 vitamin B6= 18%,127 and copper= 10%.126
However, it is also difficult to compare prevalence between studies because of
the variability in cutoffs and methods used in measuring micronutrients. Another
theory is that the status of nutrients may increase with lessened food intolerance
in the years following surgery; however, our findings suggest that micronutrient
status is not associated with the time that has elapsed since surgery.
Other novel findings from the current study are the combinations in which
these deficiencies are presented, both in the general RYGB population and in
RYGB population with anemia. Iron deficiency and its clinical manifestation,
anemia, can occur simultaneously with deficiencies in other nutrients, including
zinc and B vitamins. Also, in addition to iron deficiency, patients with anemia
presented with deficiencies in copper, zinc, vitamin B6, folate and vitamin B12.
Therefore, iron deficiency may mask these other forms of malnutrition if it is the
only nutrient that is measured. The occurrence of simultaneous deficiencies also
makes it difficult to use MCV to differentiate between the types of anemia. Eightyfive percent of the population with anemia presented with normocytic anemia, 15%
presented with microcytic anemia (generally attributed to deficiencies in iron,
copper, vitamin B6, and zinc), and no patients presented with macrocytic anemia
(generally associated with megaloblastic anemias of folate and vitamin B 12. It is
possible that most of our patients presented with normocytic anemia because
having microcytic and macrocytic anemias simultaneously may blunt the
phenotypic effects of either type of anemia and have an overall appearance of
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normal cell size. More specific tests are needed for accurate differentiation;
examining megalocytes and segmented neutrophils on a peripheral blood smear
may better detect megaloblastic anemias.
We found a significant positive correlation between dietary heme iron
intake and the number of years post-surgery. This finding suggests that
participants who were further out from surgery consumed more heme iron, which
is found in meat products. Initially, this appeared to be inconsistent with findings
of meat intolerance with little improvement up to seven years post-surgery100;
however, after removing time points greater than seven years post-surgery from
our study population, heme iron intake was no longer associated with the number
of years post-surgery. Therefore, heme iron intake may initially increase with the
increase in time following surgery (up to seven years), but heme iron intake may
ultimately plateau. Although heme iron is normally considered to be the more
bioavailable form of iron, malabsorptive procedures delay interaction between
pancreatic enzymes and biliary secretions and the food bolus until the common
channel. This has a pronounced adverse effect on heme iron absorption, as
biliopancreatic secretions are necessary for proteolytic digestion of myoglobin
and hemoglobin, and ultimately the release of heme that is available for
absorption.89,108 This phenomenon may account for why iron status did not
improve with the increase in heme iron take, and why iron status did not improve
with time following surgery.
Our patient population exceeded the RDAs for all nutrients assessed,
including iron, copper, zinc, vitamin B6, vitamin B12, folate, calcium, and vitamin C.
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However, the 2013 Update of the Clinical Practice Guidelines for the
Perioperative Nutritional, Metabolic, and Nonsurgical Support of the Bariatric
Surgery Patient recommends that RYGB patients take two adult multivitamin plus
mineral supplements daily.128 The guidelines further specify minimum daily
supplementation of 45-60 mg iron, 2 mg of copper, 400 mcg of folate, and 1000
mcg of vitamin B12. There were no specific recommendations for vitamin B 6 and
zinc. Our study population did not reach these recommended supplementation
levels for iron or vitamin B12. However, we found no association between the
intake of micronutrients and iron status or anemia, which suggests that the intake
of micronutrients may not be used to predict or treat iron deficiency or anemia.
A notable strength of this study was recruitment from the community,
rather than from one bariatric center, which is typical in the literature. Recruiting
participants from the community afforded us a representative sample of bariatric
surgery patients who obtained their surgical procedures at various clinics, who
had various lengths of elapsed time since surgery, and who had different dietary
recommendations following surgery. This representative RYGB population
sample enabled us to accurately measure the true prevalence of nutrient
deficiencies and dietary intake. A limitation was that our study was crosssectional. As a result, we cannot infer any incidence or cause-and-effect
relationships; we can only present associations. Another limitation of our study
was our sample size for the subpopulation with three-day food records; the low
number of participants in this group may explain the lack of association between
the intake of micronutrients from diet and supplements, and iron status or anemia.
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Although iron deficiency is prevalent following RYGB, there are patients
who remain normal in iron status. Therefore, our goal was to investigate other
factors that may affect iron status following surgery, including the status and
dietary intake of other nutrients implicated in iron homeostasis. In support of this
goal, we found that there were deficiencies in micronutrients involved in iron
absorption (copper), heme synthesis (vitamin B6 and zinc) and blood cell
differentiation (vitamin B12 and folate). We found that combinations of
deficiencies in these nutrients were more prevalent than isolated iron deficiency.
Additionally, we found that dietary intake of energy, fat, total protein, and animal
protein were lower in individuals with low iron stores compared to individuals with
normal iron stores. Finally, we found that patients consumed more heme iron the
further they were out from surgery. Comprehensive screening of micronutrient
status following RYGB surgery is needed in order to uncover defects in iron
nutrition following RYGB. Also, increasing consumption of foods with high
content of calories, fat and protein may predict a more favorable iron status, but
may have undesirable effects on other surgery outcomes such as weight regain.
These findings may be used to guide further investigation and develop
prophylactic

measures.
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Table 2.1 Population Characteristics
Parameters

Total Population

Population with

Population with Dietary

Anemia

Records

Sample Size

N=70

N=26

N=9

% Female

91

100

89

Race/Ethnicity

79: 14: 1

75: 25: 0

100: 0: 0

Age in Years (range)

49.4 ± 0.9 (30 to 65)

50.3 ± 1.2 (35 to 61)

48.0 ± 2.6 (30 to 58)

Years Post Surgery (range)

*4 ± 2 (0 to 33)

*4 ± 2 (0 to 12)

5.4 ± 1.7 (0 to 14)

BMI (kg/m2) (range)

*28.9 ± 2.7 (18.2 to 61.1) *26.4 ± 2.5 (21.0 to 61.1) *26.5 ± 2.7 (22.3 to 45.0)

Multivitamin Use

51: 10: 39

(% White: Black: Other)

50: 12: 38

78: 22: 0

(% Yes: No: Missing)
Table 2.1 shows the population characteristics for the total population of screened RYGB participants, the subpopulation
with anemia, and the subpopulation with completed dietary records. Age in Years, Years Post Surgery, and BMI reported
as mean ± S.E.M for normally distributed data and *median ± semi-interquartile range for skewed data.
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Table 2.2 Prevalence of Deficiencies
Type of Deficiency

Total Population

Population with Anemia

Population with

(N=70)

(N=26)

Dietary Records

number: prevalence

number: prevalence

(N=9)
number: prevalence

Iron deficiency

17: 24.3%

12: 46.2%

2: 22.2%

Zinc deficiency

14: 20.0%

6: 23.1%

1: 11.1%

Copper deficiency

2: 2.9%

2: 7.7%

1: 11.1%

Vitamin B6 deficiency

3: 4.3%

2: 7.7%

0

Folate deficiency

1: 1.4%

1: 3.8%

0

Vitamin B12 deficiency

2: 2.9%

2: 7.7%

0

31: 44.3%

1: 3.8%

5: 55.5%

No deficiency or deficiency
in other nutrients

Table 2.2 shows the types and prevalence of nutrient deficiencies related to iron homeostasis in the total screened RYGB
population, the subpopulation with anemia, and the subpopulation with completed dietary records.
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Figure 2.1. Combined deficiencies in nutrients related to iron homeostasis in the
total population (N=70). Abbreviations: Fe= iron, Cu= copper, Zn= zinc, B6=
vitamin B6, Fol= folate, B12= vitamin B12.
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Figure 2.2. Combined deficiencies in nutrients related to iron homeostasis in the
subpopulation with anemia (N=26). Abbreviations: Fe= iron, Cu= copper, Zn=
zinc, B6= vitamin B6, Fol= folate, B12= vitamin B12.
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Table 2.3 Mean daily dietary intake of post-RYGB patients
Variables

Mean ± S.E.M.

% RDA for average
participant:
(Female, Age 31-50)

Total Energy (kcal)

1650.4 ± 605.1

-

Total Fat (g)

66.5 ± 10.2

-

Total Protein (g)

77.9 ± 9.8

-

Animal Protein (g)

57.8 ± 8.6

-

Total Carbohydrate (g)

189.8 ± 28.9

-

Total Iron (mg)

41.8 ± 18.2

232.2%

Heme Iron (mg)

0.85 ± 0.18

-

Non-heme Iron (mg)

40.9 ± 18.3

-

3.1 ± 0.8

238.5%

Folate (mcg)

594.2 ± 169.1

148.6%

Vitamin B12 (mcg)

119.8 ± 112.5

4991.6%

Vitamin C (mg)

108.0 ± 30.6

144.0%

Copper (mg)

2.6 ± 0.9

288.9%

Zinc (mg)

19.7 ± 5.3

246.2%

1407.8 ± 341.0

140.8%

Vitamin B6 (mg)

Calcium (mg)

Table 2.3. Dietary intake was analyzed using NDSR software. Average ± S.E.M.
was determined using STATISTCA software. The %RDA was calculated using
the RDA for the average study participant, who was female and age 31-50.
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Figure 2.3. Associations between ferritin status as mean total energy, total fat, total protein, and animal protein in nine
RYGB patients. Normal ferritin status (dark grey bars) was defined as ferritin ≥ 20 mcg/L and deficient ferritin status (light
grey bars) was defined as ferritin < 20 mcg/L.
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Figure 2.4. Correlation (r=0.67, p<0.05) between dietary heme iron intake and years post-RYGB surgery in nine
participants. Heme iron was calculated by multiplying the iron content in meat products by 0.4. The dashed lines represent
the 95% confidence interval for the Pearson’s correlation.
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CHAPTER 3. CONCLUSIONS

3.1

Conclusions

Fifty-six percent of the total RYGB study population presented with
micronutrient deficiencies related to iron nutriture; this includes deficiencies in
iron, copper, zinc, vitamin B6, folate, and vitamin B12. This suggests that, more
often than not, patients will present with one or more deficiencies in nutrients that
affect iron status post-operatively. In addition, there is a high prevalence of
anemia (37%) in the RYGB population, which would be expected since
deficiency in iron and iron-related nutrients are so common. Of importance,
RYGB patients more commonly present with multiple deficiencies simultaneously
in nutrients related to iron homeostasis than with iron deficiency alone. Therefore,
it is vital that health providers for RYGB patients routinely perform
comprehensive assessments of micronutrient status, which includes iron as well
as zinc, copper, and the B vitamins, in order to detect and effectively treat iron
deficiency and anemia following surgery.
Dietary intake of iron (heme or non-heme) or of other micronutrients did
not appear to affect iron status or anemia. Therefore, it may not be effective to
make dietary recommendations to increase intake of iron and related nutrients
through diet and use of supplements in order to improve iron status or anemia;
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this must be confirmed in future studies. However, patients with normal ferritin
concentrations had a higher consumption of total energy, fat, protein, and animal
protein than patients with low ferritin concentrations. Although a more favorable
iron status is associated with higher fat consumption, recommending higher fat
consumption may have undesirable effects; increasing dietary fat consumption
may contribute to weight regain in the bariatric surgery population, as dietary fat
induces overconsumption and weight gain in obese and post-obese subjects.129
However, it may be worthwhile to recommend a high-protein diet in RYGB
patients to improve iron status. Since we found that heme iron intake increases
with time following surgery, it appears plausible to increase animal protein (found
in meat, which is the primary source of heme iron) in the years following surgery.
However, if patients are intolerant to animal protein in the immediate period
following surgery, other forms of protein supplementation may be needed in
order to improve iron status in these patients.
Our findings supported our hypothesis that iron deficiency occurs in
combination with deficiencies of other nutrients that effect iron status. These
nutrients include vitamin B12 and zinc. However, RYGB patients also presented
with iron deficiency alone, zinc deficiency alone, or multiple deficiencies in
nutrients excluding iron. Our findings did not support our hypothesis that dietary
intake of iron or other nutrients involved in iron homeostasis is an important
factor in determining iron status. Instead, our preliminary data suggests that
macronutrient, rather than micronutrient, intake impacts iron status. Our findings
did support our hypothesis that anemia is associated with iron deficiency as well
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as deficiencies in other nutrients following RYGB. RYGB patients with anemia
also experienced multiple deficiencies simultaneously more often than they
experienced iron deficiency alone.
Implications of these findings are that clinicians who evaluate post-RYGB
patients, especially patients who present with known symptoms or manifestations
of iron deficiency, should include copper, zinc, vitamin B6, folate, and vitamin B12
in their assessment. Although the latest Clinical Practice Guidelines for the
Perioperative Nutritional, Metabolic, and Nonsurgical Support of the Bariatric
Patient recommends postoperative evaluation of iron, zinc, and vitamin B 12, there
are no recommendations for assessment of copper, folate, or vitamin B 6. For
post-bariatric patients with anemia, these guidelines suggest evaluating vitamin
B12, folate, copper, and zinc only if routine screening for iron deficiency is
negative;128 this does not take into account the occurrence of multiple
deficiencies simultaneously, which was shown by this study to be more prevalent
than the occurrence of any deficiency in isolation. Even if a patient tests positive
for iron deficiency, this does not rule out the possibility of simultaneous
deficiencies in other nutrients. Therefore, failing to perform comprehensive
assessment of all nutrients and/or treating some deficiencies and not others will
not effectively treat these patients. Routine, comprehensive screening is
important for prevention, accurate diagnosis, and effective treatment of
micronutrient deficiencies following RYGB.
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3.2

Future Directions

In the future, it would be beneficial to increase the number of participants
with dietary records. This will allow us to have more definitive information
regarding associations between dietary intake and iron status. We would also like
to develop the appropriate micronutrient formula to effectively treat iron
deficiency through supplementation. Our preliminary findings have suggested
that RYGB patients exceed the RDA for intake of iron and related nutrients;
however, RYGB patients are at higher risk for micronutrient deficiencies than the
normal population. In support of this, the guidelines for bariatric surgery patients
recommend that RYGB patients take two multivitamin plus mineral supplements
daily, although they do not specify recommended intake of all nutrients related to
iron nutriture.128 Thus, future studies are needed to determine effective doses of
iron and other nutrients involved in iron homeostasis. Also, it would be useful to
assess dietary intake of phytates and polyphenols that are known to inhibit iron
absorption, in order to more thoroughly investigate the impact of food
constituents on iron status.
Additionally, we are in the process of developing an in-house method for
simultaneously quantifying water-soluble vitamins from plasma samples using
mass spectrometry. This is a potential cost effective method that may be used to
perform comprehensive analysis of nutrients involved in iron homeostasis, such
as the B vitamins. We hope that lowering the cost of micronutrient assessment
will facilitate the comprehensive screening that we propose will benefit the RYGB
population.
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Finally, recent evidence suggests that polymorphisms in genes that
regulate iron absorption and mobilization promote iron deficiency. Single
nucleotide polymorphisms (SNP)s in the transferrin gene, TF,

130-133

type-2

transferrin receptor gene, TFR2,134,135 and the TMPRSS6 gene132,133,135 have
been documented in humans and are associated with reduced iron status; thus
genetics may also contribute to reduced iron status following RYGB. In the future,
we would like to determine if SNPs are associated with measures of iron status in
a cross-sectional study of RYGB patients.
It is estimated that, since 1990, 1.4 million persons have undergone
bariatric surgery in the United States alone.68 Therefore, it is imperative that we
continue to perform the investigations needed in order to optimize post-surgery
health.
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